Finance

Lists
Why is BAYZF up 2,21%?
Dive Deeper
BAYZF:OTCMKTS
Bayer AG
49,06 USD
+2,21%
(+1,06) 1D
9-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BAYZF...
Open
49,06 USD
High
49,06 USD
Low
49,06 USD
Mkt. cap
48,16 млд
Avg. vol.
3,64 миң
Volume
791,00
52-wk high
61,38 USD
52-wk low
30,13 USD
Beta
0,54
Shares outstanding
982,42 млн
No. of employees
88 миң
Open
49,06 USD
High
49,06 USD
Low
49,06 USD
Mkt. cap
48,16 млд
Avg. vol.
3,64 миң
Volume
791,00
52-wk high
61,38 USD
52-wk low
30,13 USD
Beta
0,54
Shares outstanding
982,42 млн
No. of employees
88 миң
News stories
From web sources and news partners
Profile
Bayer AG is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The company is a component of the EURO STOXX 50 stock market index. Bayer was founded in 1863 in Barmen as a partnership between dye salesman Friedrich Bayer and dyer Johann Friedrich Weskott. The company was established as a dyestuffs producer, but the versatility of aniline chemistry led Bayer to expand its business into other areas. In 1899, Bayer launched the compound acetylsalicylic acid under the trademarked name Aspirin. Aspirin is on the World Health Organization's List of Essential Medicines. In 2021, it was the 34th most commonly prescribed medication in the United States, with more than 17 million prescriptions. In 1904, Bayer received a trademark for the "Bayer Cross" logo, which was, from 1910, subsequently stamped onto each aspirin tablet, creating an enduring brand image. Wikipedia
About Bayer AG
CEOBill Anderson
Employees87,8 миң
Founded1863-ж., 1-авг.
Headquarters-
SectorPharmaceutical industry
Websitebayer.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
9,66 млд
11,44 млд
13,40 млд
10,87 млд
Cost of goods sold
4,31 млд
4,23 млд
5,23 млд
4,52 млд
Cost of revenue
4,31 млд
4,23 млд
5,23 млд
4,52 млд
Research and development expenses
1,50 млд
1,29 млд
1,42 млд
1,51 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,40 млд
5,37 млд
3,70 млд
3,94 млд
Operating expense
5,90 млд
3,89 млд
4,64 млд
5,35 млд
Total operating expenses
10,20 млд
8,12 млд
9,88 млд
9,87 млд
Operating income
-543,00 млн
3,32 млд
3,53 млд
999,00 млн
Other non operating income
-7,00 млн
1,51 млд
-55,00 млн
-329,00 млн
EBT including unusual items
-1,16 млд
-3,37 млд
2,99 млд
321,00 млн
EBT excluding unusual items
-1,16 млд
4,63 млд
2,99 млд
502,00 млн
Income tax expense
-202,00 млн
378,00 млн
222,00 млн
92,00 млн
Effective tax rate
17,40%
-11,21%
7,43%
28,66%
Other operating expenses
993,00 млн
-2,76 млд
-470,00 млн
-97,00 млн
Net income
-963,00 млн
-3,76 млд
2,76 млд
219,00 млн
Net profit margin
-9,97%
-32,85%
20,61%
2,01%
Earnings per share
0,57
-
-
-
Interest and investment income
-
471,00 млн
-
-
Interest expense
-539,00 млн
-527,00 млн
-474,00 млн
-81,00 млн
Net interest expenses
-539,00 млн
-56,00 млн
-474,00 млн
-81,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
412,00 млн
4,72 млд
4,76 млд
2,16 млд
Gain or loss from assets sale
-33,00 млн
-191,00 млн
-161,00 млн
-14,00 млн
AI content may include mistakes. Learn more
Google колдонмолору